Virpax Pharmaceuticals, Inc.
Virpax Pharmaceuticals, Inc. (VRPX): 5 pipeline candidates · ~2 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.6 months
D/E -2.70 · 0% dilution
Lead: Preclinical
5 candidates
N/A
N/A
A transparent, data-derived signal for Virpax Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$14K
Cash
$1.5M
Quarterly Burn
$2.9M
Runway
1.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
Frequently asked questions
How many drug candidates are in Virpax Pharmaceuticals, Inc.'s pipeline?
Virpax Pharmaceuticals, Inc. (VRPX) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Virpax Pharmaceuticals, Inc.'s lead drug candidate?
Virpax Pharmaceuticals, Inc.'s most advanced tracked candidate is anqlar (Preclinical) for prophylactic viral barrier to inhibit viral infection by influenza or SARS-CoV-2.
What is Virpax Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Virpax Pharmaceuticals, Inc. has approximately 1.6 months of cash runway.
What is Virpax Pharmaceuticals, Inc.'s market capitalization?
Virpax Pharmaceuticals, Inc.'s market capitalization is approximately $14K.
Who is the CEO of Virpax Pharmaceuticals, Inc.?
Mr. Jatinder Dhaliwal is the chief executive officer of Virpax Pharmaceuticals, Inc. (VRPX).
Get the full picture on Virpax Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.